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Abstract Liver transplantation is the only curative
treatment in patients with end-stage liver disease. Neuro-
logical complications (NC) are increasingly reported to
occur in patients after cadaveric liver transplantation. This
retrospective cohort study aims to evaluate the incidence
and causes of NC in living donor liver transplant (LDLT)
patients in our transplant center. Between August 1998 and
December 2005, 121 adult LDLT patients were recruited
into our study. 17% of patients experienced NC, and it
occurred signiﬁcantly more frequently in patients with
alcoholic cirrhosis (42%) and autoimmune hepatitis (43%)
as compared with patients with hepatitis B or C (9/10%,
P = 0.013). The most common NC was encephalopathy
(47.6%) followed by seizures (9.5%). The choice of
immunosuppression by calcineurin inhibitor (Tacrolimus
or Cyclosporin A) showed no signiﬁcant difference in the
incidence of NC (19 vs. 17%). The occurrence of NC did
not inﬂuence the clinical outcome, since mortality rate,
median ICU stay and length of hospital stay were similar
between the two groups. Most patients who survived
showed a nearly complete recovery of their NC. NCs occur
in approximately 1 in 6 patients after LDLT and seem to be
predominantly transient in nature, without major impact on
clinical outcome.
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Abbreviations
NC Neurologic complication
TAC Tacrolimuns
CSA Cyclosporine A
AST Aspartate transaminase
ALT Alanine transaminase
ESLD End-stage liver disease
LDLT Living donor liver transplantation
Introduction
Liver transplantation (LT) has been performed since 1963
[29]. At that time all patients died from uncontrolled
bleeding or acute rejection. The ﬁrst successful liver
transplantation was performed in 1967 [28]. Since that time
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markedly, mostly due to improved peri-operative care,
operative techniques and improved immune suppressive
therapy [7, 23]. Improved long-term survival after LT has
led to increasing awareness of the occurrence of neuro-
logical complications (NC) in recent years [15, 24, 27].
NCs in patients following LT are reported to occur in up to
75% of cases [1, 8, 9, 13, 21, 22]. The main diagnoses of
NC are encephalopathy, seizure, immunosuppressant rela-
ted neurotoxicity, and peripheral nerve damage [1, 31, 32].
Due to organ shortage, the ﬁrst clinical LDLT program was
started by Broelsch [4, 5] at the University of Chicago in
1989 and has become an alternative approach for adult and
pediatric liver transplantation in many centers throughout
the world [17]. We conducted this retrospective cohort
study to evaluate the incidence of NCs in LDLT patients in
our center.
Patients and methods
The study was conducted in accordance with the Dec-
laration of Helsinki. Adult living donor liver transplant
recipients transplanted at the Department of General-,
Visceral- and Transplant Surgery, University Duisburg-
Essen, Germany between October 1998 and December
2005 were included in the analysis. Exclusion criteria
were pediatric patients (age \18 years) and incomplete
patient records. Our policy towards the selection of
patients appropriate for LDLT has been described else-
where [17, 33].
All operations were performed using standard surgical
techniques and a standardized anesthesia protocol was
applied to all patients. Patients were treated postoperatively
in a single intensive care unit applying standardized care
consisting of triple immune suppression [corticosteroids,
mycophenolatmofetile (MMF) and tacrolimus (TAC) or
cyclosporine A (CSA)], antimicrobial prophylaxis and
selective digestive decontamination [26]. Daily trough
levels of the calcineurin inhibitors (CNIs) (TAC or CSA)
were measured for adjusting the daily dose. Rejection
episodes of the graft were treated with 500 mg predniso-
lone three times daily intravenously. Renal replacement
therapy (CVVHD) was initiated if creatinine exceeded
2.5 mg/dL, if blood urea nitrogen exceeded 100 mg/dL or
if patients had impaired oxygenation due to volume over-
load. Blood samples were collected 1 day before liver
transplantation and then every morning after liver trans-
plantation until the patient was discharged from the ICU.
Laboratory routine work-up was performed daily and
included at least total bilirubin, aspartate transaminase
(AST), alanine transaminase (ALT), creatinine, c-reactive
protein (CRP), hemoglobin, leukocytes, platelets and
international normalized ratio (INR). The follow-up was
1 year for all patients.
Deﬁnition
Diagnoses of NCs were assessed by neurologic examina-
tion, cerebral computed tomography (cCT) or cerebral
magnetic resonance tomography (cMRT). A central ner-
vous system complication was considered to occur when
there was clinical and/or radiologic evidence of central
nervous system damage which was not associated with a
poor graft function, sepsis or other diseases that could be
associated with central nervous system signs. Delirium,
stupor and coma with regular cCT or cMRT images were
grouped under the term encephalopathy.
Clinical examinations were performed by the ICU and
transplantation staff. The clinical diagnoses were con-
ﬁrmed by neurologists.
Statistical analyses
Categorical variables were analyzed by the Chi-squared test
with Yates correction. Continuous variables were analyzed
by the one-way analysis of variance and t test, when normal
distributionwasgiven.Non-normallydistributedcontinuous
variables were analyzed by the Kruskal–Wallis one-way
analysis of variance on ranks.
The Mann–Whitney Rank Sum test was performed
when the equal variance test failed; P\0.05 was consid-
ered signiﬁcant. Data are presented as mean ± SD.
Results
Patients
From October 1998 to December 2005, 167 living donor
transplantations were performed at the surgical department
of the University of Essen; of these 34 were transplanta-
tions in pediatric patients that were not enrolled into the
study. Twelve of the 133 adult LDLT patients had
incomplete records, so were also excluded from the study.
Complete medical records of the remaining 121 adult
patients were retrospectively reviewed. The primary liver
diagnoses are listed in Table 1.
Incidence of neurological complications
After LDLT, 17% of patients (10 men, 11 women, age
48 ± 14) experienced NCs. The most common complica-
tion was encephalopathy, including somnolence, mental
alteration and confabulation, which occurred in ten
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123patients. Two patients experienced seizures, another two
developed peripheral polyneuropathy. The trough levels of
CSA or TAC at the time of NC onset were in the thera-
peutic range (for TAC 8–15 ng/ml, for CSA 200–250 ng/
ml). Miscellaneous complications occurred in seven
patients [posterior leucencephalopthy (1), ischemic stroke
(1), intracerebral bleeding (1), heparin-induced thrombo-
cytopenia related ischemia (2), subarachnoidal hemorrhage
(1), and pontine myelinolysis (1), see Table 2]. The patient
with the ischemic stroke suffered from post transplant
diabetes, whereas the patient with the intracerebral hem-
orrhage suffered from hypertension.
The occurrence of NC could not be explained by dif-
ferences in MELD score, ICU- hospital stay or cold- and
warm ischemia time between the groups (see Table 3).
52% of patients that experienced NC (11/21 patients)
already showed pretransplant signs of advanced encepha-
lopathy, as opposed to 15% (15/100 patients) in the group
without NC (P\0.001).
In both patient groups the clinical course of the trans-
planted liver graft was normal and did not differ signiﬁ-
cantly (see Table 4). We recorded a signiﬁcant decline of
AST on admission compared with 1 week following
transplantation within each group. Bilirubin remained
nearly the same 1 week after transplantation as compared
with the value on admission to the ICU. Renal function,
expressed as serum creatinine concentrations, did not alter
during the ﬁrst week following transplantation in either
group (see Tables 4, 5).
Most NCs (90%) were encountered in the ﬁrst month
after LT. In the majority of cases, encephalopathy (80%)
and seizure (60%) presented in the ﬁrst 2 weeks. Only one
patient experienced NC after hospital discharge.
Effect of the primary diagnosis on NC
Viral hepatitis and alcoholic cirrhosis were the main causes
of pre-operative liver decompensation (see Table 1). 42%
of the alcoholic group and 43% of the autoimmune group
showed the highest rate of NCs. The incidence of NC in
these groups was signiﬁcantly higher as compared to
patients with hepatitis B or hepatitis C (9.4%, P = 0.006
and P = 0.04, respectively).
Patients with autoimmune hepatitis received signiﬁ-
cantly more immunosuppressive drugs preoperatively, such
as prednisone or azathioprine, as compared with patients
suffering from PBC or PSB [4/7 (57%) vs. 2/17 (12%),
P = 0.02].
Table 1 Primary diagnoses
Underlying disease Number of patients (%)
Hepatitis C 43 (36)
Hepatitis B 21 (17)
Alcoholic cirrhosis 14 (12)
PBC/PSC 17 (14)
Autoimmune hepatitis 7 (6)
Cryptogenic 9 (7)
Miscellaneous 10 (8)
Total 121 (100)
Miscellanous: Cholangiocellular carcinoma (2), Klatskin tumor (1),
M. Wilson (1), Neuroendocrine tumor (2), acute intermittent por-
phyria (1), sarcoma of the liver (1), hemangiosarcoma of the liver (1),
a1 antitrypsine deﬁciency (1)
PBC primary biliary cirrhosis, PSC primary sclerosing cirrhosis
Table 2 Type of neurological complication
Complication Number Incidence (%)
Encephalopathy 10 48
Seizure 2 10
Peripheral polyneuropathy 2 10
Miscellaneous
a 73 3
Total 21
a Miscellaneous diagnoses see text
Table 3 Perioperative patients’ data
Patients with NC Patients without NC
MELD score 18 ± 21 6 ± 1
Ventilation time in h 106 ± 34 99 ± 25
ICU stay in days 12 ± 41 1 ± 2
Hospital stay in days 37 ± 65 8 ± 27
WIT (min) 43 ± 94 2 ± 4
CIT (min) 224 ± 28 225 ± 13
GBWR 1.05 ± 0.2 1.1 ± 0.25
1 Year survival (%) 74 70
All data are given as mean ± SD
WIT warm ischemia time, CIT cold ischemia time, GBWR graft body
weight ratio
Table 4 Course of AST, bilirubin and creatinine
Patients with NC Patients without NC
Day 0 Day 7 Day 0 Day 7
AST (U/L) 340 ± 58 43 ± 12* 295 ± 49 69 ± 15*
Bilirubin (mg/
dL)
6.6 ± 1 9.8 ± 1.8 6.4 ± 0.5 6.9 ± 0.8
Creatinine (mg/
dL)
1.2 ± 0.13 1.2 ± 0.14 1.3 ± 0.07 1.5 ± 0.14
Day 0: day of admission, Day 7: 1 week following transplantation
NC neurological complication
Values are given as mean ± SD
* P\0.05
J Neurol (2010) 257:253–258 255
123Inﬂuence of neurologic complications on outcome after
LDLT
The occurrence of NC in patients after LDLT did not
inﬂuence the main clinical outcome parameters median
ICU stay, length of hospital stay or one year survival (see
Table 3). The long term neurological function did not
differ between the groups.
Effect of the calcineurin inhibitor on neurological
complications
CSA was the predominantly used immunosuppressant in
our cohort (78 of all patients), whereas 43 patients were
treated with TAC. NCs occurred in 19% of TAC treated
patients, and in 17% of the CSA-group (P = 0.9).
Discussion
The present study shows that NCs occur frequently after
LDLT. The reported incidence of NC after cadaveric liver
transplantation ranges from 10 to 75% [8, 9, 13, 21, 22]. In
thepresentstudytherateofNCswas17%.Themainclinical
outcome parameters median ICU stay, hospital stay and one
year survival rate did not differ between patients with and
without NC. The MELD score and graft function were
comparable in patients with and without NCs. Patients with
alcoholic and autoimmune related cirrhosis showed a
signiﬁcant higher rate of NCs as compared with other diag-
noses. Development of NC after LDLT was related to
pre-transplantdeteriorationinneurologicalfunction,butwas
not inﬂuenced by type of immunosuppressant used.
The incidence of NC in 17% of patients observed in our
study is comparable with other reports. Kim et al. [15]
reported an incidence of 15.4% of NC in their LDLT
patients. The incidence of NC in LT patients with a
deceased donor was recorded to be 25% in the group of
Mueller [20]. The highest incidence of NCs in LT patients
with a deceased donor was mentioned by Ghaus et al. [13]
with an incidence of 75%. The reason for the higher inci-
dence of NC in the Ghaus study [13] may be the smaller
number of evaluated patients (21 vs. 45 patients), whereas
the Mueller study [20] recruited 130 patients. Moreover,
Ghaus [13] et al. also included peripheral neurologic dis-
orderssuch as tremor, which may be responsible for this
high incidence of 75% in their study.
Diffuse encephalopathy is considered to be the main NC
in patients after liver transplantation [19]. Encephalopathy
was also the main NC in the present study, with an inci-
dence rate of 48%. The cause of post-transplant encepha-
lopathy in patients with a primary functioning graft
remains unclear. Post mortem results of an anecdotal study
indicate anoxic–ischemic changes as the main neuro-
pathological ﬁndings, which could be the cause of
encephalopathy [10].
The second most common cause of NC in LT patients
is seizures. The reported incidence is up to 20% [16, 22].
In our study the incidence of seizures was 10% and
conﬁrmed previous data from our group, which indicates
an incidence of 11.6% [22]. In the recent 10 years the
rates of seizures seems to have declined. One center
reported a reduction in the incidence of seizures in
patients following LT from 42% [34]t o0 %[ 31] at two
different time periods. The reasons for this reduction
could be improved postoperative intensive care,
improvement in accurate diagnosis and treatment of
metabolic disorders, and improved immunosuppressive
drugs with fewer side effects.
In the present study, one patient developed central
pontine myelinolysis (CPM). CPM was ﬁrst described in
1959 [2] and ﬁrst reported after a liver transplantation in
1978 [30]. CPM presents symmetrical demyelinating
lesions at the center of the pons. Despite being ﬁrst
described in alcoholics and malnourished patients, several
reports describe its occurrence in patients after liver
transplantation, with incidence rates ranging between 1.2
and 10% [3, 6]. Due to study design, the incidence of CPM
in autopsy studies is signiﬁcantly higher as compared with
clinical studies.
The etiology and pathogenesis of CPM remains unclear,
though rapid correction of hyponatremia seems to be a
main factor which triggers this syndrome with signs of
dysarthria, paraperesis or quadriparesis [36]. The patient in
our report died due to lack of causative treatment. How-
ever, in some selected cases a combination of plasmaphe-
resis and immunoglobulins could be considered as a rescue
treatment [25].
Table 5 Effect of primary diagnosis on neurologic complication
Underlying disease All patients Patients with NC
post-LT (incidence of NC)
Hepatitis C 43 4 (9%)
Hepatitis B 21 2 (10%)
Alcoholic cirrhosis 14 6 (42%)
PBC/PSC 17 2 (12%)
Autoimmune hepatitis 7 3 (43%)
Cryptogenic 9 3 (33%)
Miscellaneous 10 3 (30%)
Total 121
PBC primary biliary cirrhosis, PSC primary sclerosing cirrhosis, NC
neurologic complication, LT liver transplantation
Miscellanous: Cholangiocellular carcinoma (2), Klatskin tumor (1),
M. Wilson (1), Neuroendocrine tumor (2), acute intermittent por-
phyria (1), sarcoma of the liver (1), hemangiosarcoma of the liver (1),
a1 antitrypsine deﬁciency (1)
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123Furthermore, one patient developed posterior leukoen-
cephalopathy (PLE), which was ﬁrst described in 1996
[14]. This illness was recognized as a reversible syndrome
of headache, visual abnormalities and hemipareses induced
by severe hypertension. After successful treatment of
hypertension all patients recovered. However, our group
published a case of a LDLT patient, who developed a TAC
related PLE 3 months after transplantation. On admission
she was comatose and remained unconscious until she died
[12].
It has been documented that the incidence of NC is
higher in patients receiving liver grafts from deceased
donors for alcoholic and primary biliary cirrhosis [16]. In
contrast to our data, Kim et al. [15] did not ﬁnd a rela-
tionship between NCs and primary liver diagnosis in LDLT
patients. Our data indicate a signiﬁcant higher rate of NC in
patients who received a transplant for alcoholic liver dis-
ease and autoimmune hepatitis.
In our study the survival rate of patients with or without
NC did not differ signiﬁcantly. In a prospective clinical
trial, Pujol et al. [21] showed a signiﬁcant higher mortality
rate for liver transplant patients with NC as compared to
those without (55 vs. 17%), whereas Wijdecks et al. [35]
indicate no impact of NC on mortality.
The relationship between immunosuppressive therapy
and the development of NC has been well established for
calcineurin inhibitors [20]. McDiarmid [18] reported a
higher incidence of NC in TAC based immunosuppression
regime as compared with CSA. The incidence of major
NCs such as coma, seizures, and encephalopathy occurred
only in the TAC group. This observation is supported by
the study of Mueller [20], who showed a signiﬁcantly
higher incidence of NC in patients treated with TAC as
compared with CS. However, both authors initially used
the intravenous formulation of TAC, which is recognized
as inducing more neurologic complications than TAC
administered via the oral route. Freise [11] and Lewis [16]
did not ﬁnd higher rates of NC in patients treated with TAC
as compared with CSA. These data are supported by the
present study.
In conclusion, the present report emphasises the frequent
development of NCs following liver transplant patients. A
careful recognition, diagnosis of central nervous system
lesions and prompt treatment is necessary.
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